Cancel
David Wustrow, Ph.D.
Senior Vice President, Drug Discovery and Preclinical Development
@
Rapt Therapeutics
fjlq54@3y86.5l3
Sign up to see email
Known information
- Joined RAPT Therapeutics in 2016
- Previously served as Vice President, Chemical and Pharmaceutical Sciences at Cleave Biosciences
- Led chemistry efforts directed towards the discovery and development of first-in-class drug products for solid and hematologic malignancies
- Held several escalating positions at biotechnology and pharmaceutical companies including Vice President, Medicinal Chemistry and Executive Director of Scientific Assessment and Licensing at XenoPort
- Was Executive Director of Chemistry at Neurogen
- Served as Senior Director of Neuroscience Chemistry at Pfizer, leading cross-functional teams to deliver preclinical development candidates for the treatment of pain, inflammation and psychiatric disorders
- Received a B.S. from Pennsylvania State University
- Holds a Ph.D. in Organic Synthesis from The University of Rochester
- Author of over 40 peer-reviewed publications
- Inventor on over 30 U.S. patents
About Rapt Therapeutics
Rapt Therapeutics, headquartered in South San Francisco, develops oral therapies for inflammatory diseases and cancer, focusing on modulating the immune system through its proprietary drug discovery engine.
Report inaccurate information
